Stock Analysts’ Updated EPS Estimates for February, 14th (ADMP, BDSI, BMY, CMG, CNP, COP, ESRX, FUN, GCO, GM)

Stock Analysts’ updated eps estimates for Wednesday, February 14th:

Adamis Pharmaceuticals (NASDAQ:ADMP) was given a $5.00 target price by analysts at Maxim Group. The firm currently has a buy rating on the stock.

BioDelivery Sciences International (NASDAQ:BDSI) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “BioDelivery has secured improved positioning in six new managed care contracts providing preferred access to its key drug, Bunavail, since July 2016. This is expected to boost the drug’s sales and profitability in turn. Meanwhile, its second marketed drug, Belbuca, recently received an approval in Canada for severe pain that should support further sales growth. BioDelivery’s shares have significantly outperformed the industry in the last one year. However, the company suffered a setback with the discontinuation of clonidine topical gel for management of painful diabetic neuropathy in December 2016. BioDelivery’s portfolio as well as its pipeline candidates may also face a severe competition as it targets a highly genericized and crowded market.”

Bristol-Myers Squibb (NYSE:BMY) was given a $51.00 target price by analysts at BMO Capital Markets. The firm currently has a sell rating on the stock.

Chipotle Mexican Grill (NYSE:CMG) had its hold rating reaffirmed by analysts at William Blair.

CenterPoint Energy (NYSE:CNP) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $30.00 target price on the stock. According to Zacks, “CenterPoint Energy's share price has outperformed the broader industry in the last one year. The company has been strengthening its infrastructure through regular capital investment and acquisitions, which will help it to meet the requirements of an expanding customer base. Toward this end, the company continues with its capital expenditure plan of $7 billion from 2017 through 2021. It also received an approval for its transmission cost of service (TCOS) filing, which is projected to provide a $7.8 million annual increase in revenue. CenterPoint Energy is also investing substantially to expand its operations to cope with increasing utility demand. The company is currently focused on upgrading infrastructure and improving reliability. However, its results are subject to the impact of weather patterns, regulatory and judicial proceedings along with fluctuating commodity prices.”

ConocoPhillips (NYSE:COP) was upgraded by analysts at Zacks Investment Research from a hold rating to a strong-buy rating. They currently have $61.00 price target on the stock. According to Zacks, “ConocoPhillips is one of the largest exploration and production players in the world, based on proved reserves and production. We appreciate the company’s initiative to divest non-core assets as the explorer could divert the proceeds toward oil-rich Eagle Ford shale and Permian Basin. It is to be noted that during 2017, ConocoPhillips generated $16 billion from the asset sale program. Significant undrilled locations in the Eagle Ford shale will boost the company’s production. ConocoPhillips got an approval from the board of directors to hike the quarterly dividend to 28.5 cents per share from 26.5 cents, representing an increase of 7.5%. The company also enhanced its share buyback program. With this, ConocoPhillips will increase share repurchases during 2018 to $2 billion from the prior projection of $1.5 billion. Also, the company’s earnings surprise history is impressive.”

Express Scripts (NASDAQ:ESRX) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $82.00 price target on the stock. According to Zacks, “Over the last year, Express Scripts has outperformed the broader industry in terms of price. The company’s solid guidance for fiscal 2017 holds promise. Express Scripts’ Multiple Sclerosis Care Value Program and SafeGuardRx solutions are likely to expand the customer base. The company recently inked an agreement to acquire eviCore healthcare for $3.6 billion. Express Scripts' pharmacy-benefit management segment (PBM) coupled with eviCore's complementary medical-benefit solutions is likely to build a comprehensive PBM solution worldwide. On the flip side, the company recently announced that its biggest customer and leading health insurer Anthem is not likely to extend its PBM agreement with Express Scripts anymore. Persistent drug pricing issue is also anticipated to affect the stock. Intensifying competition also adds to the woes.”

Cedar Fair (NYSE:FUN) was given a $77.00 price target by analysts at KeyCorp. The firm currently has a buy rating on the stock.

Genesco (NYSE:GCO) was given a $40.00 target price by analysts at Piper Jaffray Companies. The firm currently has a buy rating on the stock.

General Motors (NYSE:GM) (TSE:GMM.U) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $46.00 target price on the stock. According to Zacks, “General Motors reported fourth-quarter 2017 adjusted earnings per share of $1.65, beating the Zacks Consensus Estimate of $1.34.During the quarter, revenues also surpassed the the Zacks Consensus Estimate.For any fourth quarter, adjusted EBIT set a record. This was aided by sales of crossovers, strong pricing and cost-control initiatives, which were partly offset by a wholesale volume decline. Also, the company outperformed the industry it belongs to over the last six months. The company’s capital allocation strategy, initiatives to make its vehicles more advanced, safer and fuel efficient and focus on technology development are likely to benefit. Its restructuring activities are also expected to benefit in the long run. Also, the company is raising investment in emerging markets to boost global sales. Howrver, weak used car pricing, a challenging pricing environment as well as more pressure on commodity costs are headwinds before it.”

Intercept Pharmaceuticals (NASDAQ:ICPT) was given a $58.00 target price by analysts at Cantor Fitzgerald. The firm currently has a hold rating on the stock.

Interpublic Group of Companies (NYSE:IPG) had its hold rating reiterated by analysts at Wells Fargo & Co. The analysts wrote, “We believe IPG’s assets are broadly competitive and that investors place too much emphasis on the scale argument across the agency landscape. However, we acknowledge an array of headwinds currently facing the agency holding companies and, amid this backdrop, we view current valuation as full. DISCLOSURE APPENDIX Required Disclosures Additional Information Available Upon Request I certify that: 1) All views expressed in this research report accurately reflect my personal views about any and all of the subject securities or issuers discussed; and 2) No part of my compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by me in this research report. Wells Fargo Securities, LLC and/or its affiliates, have beneficial ownership of 0.5% or more of any class of the common stock of The Interpublic Group of Companies, Inc.””

GEE Group (NYSEAMERICAN:JOB) was given a $8.00 target price by analysts at Maxim Group. The firm currently has a buy rating on the stock.

McKesson (NYSE:MCK) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $164.00 target price on the stock. According to Zacks, “McKesson ended the third quarter fiscal 2018 on a solid note with earnings and revenues both ahead of the Zacks Consensus Estimate. Apart from the company’s balanced segmental and geographic show, we are upbeat about the recent acquisition of RxCrossroads which should strengthen the company’s foothold in pharmaceutical and biotechnology space. Among other buyouts, the purchase of retailer Well.ca is expected to bring online commerce capabilities and digital experience to McKesson Canada's retail assets. The company’s strong guidance for fiscal 2018 holds promise. McKesson has had an impressive run on the bourse in the last three months. On the flipside, stiff competition, currency headwind, reimbursement issues remain challenges. Pricing pressure in the independent retail pharmacy channel is a headwind. Particularly, McKesson’s sell-side pricing environment continues to remain competitive with less pricing variability.”

Paylocity (NASDAQ:PCTY) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Paylocity’s Q2 top and bottom line surpassed the respective Zacks Consensus Estimate and marked year-over-year improvement as well. Outlook for Q3 and FY18 were also encouraging. We remain positive about Paylocity’s regular investments in SaaS technology. For the last few quarters, clients moving from traditional payroll service providers to the company’s SaaS-based services contributed significantly to its revenues. Hence, regular investments in technological upgrades, along with product innovation, will continue to boost the company’s top line. Also, higher adoption of Paylocity’s ACA dashboard application, specializing in tracking employee count, employee status and health care plan affordability, will act as a tailwind. Notably, Paylocity has outperformed the industry in the last one year. However, competition in the payroll processing sector from new entrants as well as existing players remains a major headwind.”

Progressive (NYSE:PGR) was given a $57.00 target price by analysts at Wells Fargo & Co. The firm currently has a hold rating on the stock.

Rowan Companies (NYSE:RDC) had its hold rating reissued by analysts at Piper Jaffray Companies. Piper Jaffray Companies currently has a $17.00 price target on the stock.

Sunstone Hotel Investors (NYSE:SHO) was given a $17.00 price target by analysts at Robert W. Baird. The firm currently has a hold rating on the stock.

Sonoma Pharmaceuticals (NASDAQ:SNOA) was given a $7.00 target price by analysts at Maxim Group. The firm currently has a buy rating on the stock.

Receive News & Ratings for Adamis Pharmaceuticals Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals Corp and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply